We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Patient-reported Outcomes in the Treatment of Schizophrenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00230828
First Posted: October 3, 2005
Last Update Posted: September 12, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Solvay Pharmaceuticals
September 12, 2005
October 3, 2005
September 12, 2013
May 2005
January 2006   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00230828 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Patient-reported Outcomes in the Treatment of Schizophrenia
Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia. A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Schizophrenia
Drug: bifeprunox
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
January 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participate in S1543003 and S1543004 in the U.S. sites

Exclusion Criteria:

  • Participate in S1543003 and S1543004 other than U.S. sites
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00230828
S154.3.005
Not Provided
Not Provided
Not Provided
Not Provided
Solvay Pharmaceuticals
Not Provided
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
Solvay Pharmaceuticals
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP